NEW YORK (GenomeWeb News) – Pressure BioSciences said in its quarterly earnings document that it may not be able to fund its operations beyond next month.

In its Form 10-Q filed with the US Securities and Exchange Commission on Thursday, the South Easton, Mass.-based company said that as of June 30, it had $113,663 in cash and cash equivalents and warned that it will need "substantial additional capital" to fund operations beyond the end of September 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.